welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer jumps on 7-year-old data
Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.
The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.
expertly curated content related to this topic
-
Ehlers Danlos Syndrome (Ash)Information on Ehlers-Danlos Syndrome...
-
Sunshine and SpoonsI'm Hannah, a mom of four who loves Jesu...
-
Animal Model of Human Disease: Ehlers-Danlos SyndromeThe Ehlers-Danlos syndrome (ED-S) of dog...
-
Headaches and Hypermobilityhttps://www.oneedsvoice.com/wp-content/u...
-
Patient Education Program and Ehlers-Danlos Syndrome (PREDUSED)The Ehlers-Danlos Syndrome (SED) compris...
-
Ehlers-Danlos Syndrome or Disease?Although first described in 1892 by Tsch...
-
Ehlers-Danlos syndrome (Satumaan)Zebra is the mascot for Ehlers Danlos sy...
